Panacea Biotech gets $8.9-million additional vaccine orders from UNICEF

Panacea Biotech received an update to its UNICEF contract for supplying the WHO pre-qualified pentavalent vaccine, Easyfive-TT (DTwP-HepB-Hib), for 2023-2027. Shares of Panacea Biotech closed at ₹359.50, up 0.93% on the NSE today, December 24.

Leave a Reply

Your email address will not be published. Required fields are marked *